|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Sutent cap[紓癌特 膠囊] information |
|
|
|
製造商 |
Pfizer |
|
代理/經銷商 |
Arich |
|
成份 |
Sunitinib |
|
適應症 |
Treatment of GI stromal tumor after disease progression on or intolerance to imatinib mesylate. Treatment of advanced or metastatic renal cell carcinoma (clear cell carcinoma in pathology). |
|
用量 |
50 mg daily for 4 weeks, followed by 2 weeks off. Dose increase or reduction of 12.5-mg increments is recommended based on individual safety & tolerability. |
|
過量 |
View Sutent[紓癌特] overdosage for action to be taken in the event of an overdose. |
|
用法 |
May be taken with or without food |
|
美國食品藥物管理局之懷孕等級 |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
禁忌 |
Pregnancy. Women of childbearing potential should avoid becoming pregnant while receiving treatment. |
|
注意事項 |
Women of childbearing potential should avoid becoming pregnant during treatment. Periodic monitoring of LV ejection fraction while receiving therapy. Monitor patients for signs & symptoms of CHF for patients who presented with cardiac events such as MI (including severe/unstable angina), coronary/peripheral artery bypass graft, symptomatic CHF, cerebrovascular accident or transient ischemic attack or pulmonary embolism within the previous 12 months. History of QT prolongation, patients taking antiarrhythmics or patients with relevant pre-existing cardiac disease, bradycardia or electrolyte disturbances. Periodic monitoring with on-treatment ECG & electrolytes. Monitor for hypertension, hemorrhagic events, hypothyroidism. Monitor adrenal function in case of stress such as surgery, trauma, or severe infection. CBCs & serum chemistries should be performed at the beginning of each treatment cycle. Lactation. Children. |
|
不良反應 |
Fatigue, asthenia, diarrhea, nausea, mucositis/stomatitis, vomiting, dyspensia, abdominal pain, constipation, hypertension, rash, hand-foot syndrome, skin discoloration, altered taste, anorexia & bleeding. Potentially serious adverse reactions of LV dysfunction, QT interval prolongation, hemorrhage, hypertension & adrenal dysfunction.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Grapefruit & CYP3A4 inhibitors eg. Ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole may increase sunitinib concentration. CYP3A4 inducers eg. Dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarb, St. John's Wort may decrease sunitinib concentration.
View more drug interactions with Sutent[紓癌特] |
|
儲存 |
View Sutent[紓癌特] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Sutent[紓癌特] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Sutent[紓癌特] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Sutent 膠囊 |
|
Sutent 12.5 mg x 28's |
 |
|
|
|
Manufacturer: |
Pfizer |
|
Distributor: |
Arich |
|
|
|
|
